Sharda Cropchem posts PAT of Rs 31 crore in Q3; records volume growth of 49%

Sharda Cropchem Limited, a fast-growing IP driven Agrochemicals Company with a peer position in the generic crop protection chemicals industry, has announced its unaudited financial results for the quarter and nine months ended 31st December 2024.

Consolidated Financial Highlights

Business Wise Revenue Break up

Product Wise Revenue Break up

Region Wise Revenue Break up (Agrochemical Business)

Dividend: The Board has declared an Interim Dividend of Rs.3/- per Equity Share of Face Value of Rs. 10 each of the Company (30% of Face Value).

Key Business Highlights for Q3 FY25

• Agrochemical Segment contributes 83%; Non-Agrochemical Segment contributes 17%

• Overall Volumes have increased by 49.1% Y-o-Y in Q3 FY25; Agrochemical volumes grew by 49.5% & Non-Agrochemical volumes grew by 42.4%

• Europe, NAFTA and LATAM have been key contributors for the volume growth

Key Business Highlights for 9M FY25

• Agrochemical Segment contributes 84%; Non-Agrochemical Segment contributes 16%

• Overall Volumes have increased by 36.8% Y-o-Y in 9M FY25; Agrochemical volumes grew by 40.8% & Non-Agrochemical volumes de-grew by 12.4%

• Capex in 9M FY25 stands at Rs. 268 crores

• Product Registrations stand at 2,948 with 1,047 applications globally pending at various stages as on 31st December 2024

• The Company remains Debt free with cash, bank and liquid investments of Rs. 742 crores

Commenting on the Results, Mr. Ramprakash Bubna, Chairman and MD, said,

″Despite the ongoing global headwinds and persistent pricing pressures, we have seen a revival in demand which has led to a strong performance in Q3 FY25.

Revenue in Q3 FY25 increased by 47%, primarily driven by higher volumes. We saw volume growth across all regions, with Europe, NAFTA and LATAM being key drivers. Agrochemical volumes grew by 49.5% in Q3 FY25. With raw material prices stabilising, we have managed to expand the gross margin by 660 bps to 32.7%. We have been working on cost optimization strategies and with operating leverage playing out, we have been able to improve our EBITDA Margins to 16.9% for the quarter.

Our strong pipeline of registrations showcases our resilience and our commitment to growth which establishes a solid foundation for continued progress.

We are confident on our ongoing plan to increase product registrations in FY25 with capex guidance of Rs. 400-450 crores enabling us to meet FY25 guidance.″